Lumida
/BMRN
⌘K
BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc

BMRN
$65.68USD+0.26%+0.17 today

MARKET CAP

12.7B

P/E (TTM)

47.9x

FWD P/E

DAY RANGE

$65 – $66

52W RANGE

$49
$71

AI Summary

Stalk
StalkMedium

BMRN is consolidating within its Stage 2 advance after a blow-off peak, maintaining a medium-term bullish bias above the rising 50-day and 200-day SMAs. Short-term momentum is neutral with 9- and 20-day EMAs flat and RSI near mid-range, offering no immediate entry edge. A pullback to the 50-day SMA (around $63) or the lower end of the recent $64–$68 range would provide a lower-risk opportunity. Stalk for a test of support before initiating longs.

  • Q2 2026 revenue $989.7M (+20% YoY), non-GAAP operating margin 36.4%.
  • Raises full-year 2026 sales guidance to $3.88–$3.93B on strong product demand.
  • Acquisition financing adds ~$200M annual interest expense, pressuring earnings.
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$1.8B$2.1B$2.4B$2.9B$3.2B
YoY %-0.8%+13.5%+15.4%+18.0%+12.9%
P / Sales8.8x9.1x7.8x4.5x3.6x
EV / Sales9.4x9.6x8.2x4.7x3.7x
Gross Profit, Adj.$1.4B$1.6B$1.9B$2.3B$2.5B
YoY %+3.0%+15.8%+18.5%+20.5%+10.1%
Margin %74.5%76.0%78.0%79.7%77.7%
EV / Gross Profit12.6x12.6x10.6x5.9x4.8x
EBITDA, Adj.$25.7M$141.5M$290.2M$570.6M$489.0M
YoY %+60.1%+450.6%+105.1%+96.7%-14.3%
Margin %1.4%6.7%12.0%20.0%15.2%
EV / EBITDA673.5x141.8x68.7x23.3x24.4x
EBIT$-82.3M$39.5M$185.8M$474.2M$409.5M
YoY %+7.6%+148.0%+370.2%+155.3%-13.7%
Margin %-4.5%1.9%7.7%16.6%12.7%
EV / EBIT-210.2x507.7x107.2x28.1x29.1x
Net Income$-64.1M$141.6M$167.6M$426.9M$348.9M
YoY %-107.5%+320.9%+18.4%+154.6%-18.3%
Net Margin-3.5%6.8%6.9%15.0%10.8%
EPS (GAAP)-$0.35$0.75$0.87$2.21$1.80
YoY %-107.8%+314.3%+16.0%+154.0%-18.6%